Treatment of aggressive pelvic fibromatosis with interferonTreatment of aggressive pelvic fibromatosis with interferon
Faculty of Medicine and Health Sciences
Antwerp Surgical Training, Anatomy and Research Centre (ASTARC)
2015New York, 2015
Obstetrics and gynecology / American College of Obstetricians and Gynecologists. - New York
126(2015):6, p. 1219-1221
University of Antwerp
BACKGROUND:Fibromatosis is a rare, noninvasive but aggressive tumor. The tumor displaces tissue by pushing the normal structures aside. Optimal treatment should be individualized.CASE:A 35-year-old woman presented with a recurrent fibromatosis, which filled the vagina and extended into the pelvis. The classical surgical removal would have had a high morbidity. Therefore, it was decided, after shared decision-making, to opt for treatment with interferon. The side effects of the therapy were tolerable, and a complete regression of the fibromatosis was achieved. At present, 13 years after the diagnosis and 7 years after discontinuation of the therapy, the patient is well with no signs of disease.CONCLUSION:Interferon may be considered as primary treatment for extensive pelvic fibromatosis.